ea0070aep1081 | Hot topics (including COVID-19) | ECE2020
An Zhenmei
, Lei Ting
, Duan lian
, Zhang Lihui
, Zhou Su
, Shi Xiaofeng
, Feng Gu
Background: The LANTERN study (NCT02493517) has demonstrated that lanreotide autogel (LAN ATG) was non-inferior to lanreotide prolonged release (LAN PR) in Chinese patients with active acromegaly. This post hoc analysis of the LANTERN study assessed the impact of tumor size on treatment effect.Design: In the LANTERN study, LAN ATG was started at 90 mg and subsequently titrated according to GH and IGF-1 levels for 32 weeks. Tumor diameters > 10 mm wer...